Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel-Reference-Cited by-同舟云学术

Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel

Published:2022-09-16 Issue:14 Volume:63 Page:3385-3393
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Fried Shalev¹²^ORCID,Shouval Roni¹²³⁴^ORCID,Varda-Bloom Nira⁵,Besser Michal J.⁶⁷,Yerushalmi Ronit¹²,Shem-Tov Noga¹²,Danylesko Ivetta¹²,Jacoby Elad²⁸,Teihman Shlomit⁵,Itzhaki Orit⁷,Fein Joshua A.⁹,Kedmi Meirav¹²¹⁰,Shimoni Avichai¹²,Nagler Arnon¹²,Avigdor Abraham¹²^ORCID

Affiliation:

1. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel

2. Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

3. Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

4. Weill Cornell Medical College, New York, NY, USA

5. Hematology Laboratory, Chaim Sheba Medical Center, Tel Hashomer, Israel

6. Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv, Israel

7. Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel

8. Department of Pediatric Hematology-Oncology, Safra Children’s Hospital, Chaim Sheba Medical Center, Tel Hashomer, Israel

9. University of Connecticut Medical Center, Farmington, CT, USA

10. The Mina and Everard Goodman faculty of life sciences, Bar Ilan University, Ramat Gan, Israel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2123232

Reference23 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

3. Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

4. Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

5. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results;Leukemia;2024-03-15

2. Promises and challenges of a decentralized CAR T-cell manufacturing model;Frontiers in Transplantation;2023-09-05

3. Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma;Leukemia & Lymphoma;2023-08-11

4. Tisagenlecleucel;Reactions Weekly;2023-03-04